• 1
    Wani MC, Taylor HL, Wall MC, et al. Plant antitumor agents: V1. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971; 93: 23252327.
  • 2
    Schiff PB, Fant J., Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature 1979;22:665667.
  • 3
    Rowinsky EK, Donehower RC. Antimicrotubule agents. In: ChabnerBA, LongoDL, eds. Cancer Chemotherapy and Biotherapy, 3rd ed. Philadelphia , PA : Lippincott Williams & Wilkins; 2001: 348355.
  • 4
    National Cancer Institute Clinical brochure: Taxol (NSC 125973). Bethesda , MD : Division of Cancer Treatment, National Cancer Institute; 1983:612.
  • 5
    Rowinsky EK, Cazenave LA, Donehower RC. Taxol: A novel investigational antineoplastic agent. J Natl Cancer Inst 1990;82:12471259.
  • 6
    Donehower RC, Rowinsky EK, Groshow LB, et al. Phase I trial of Taxol in patients with advanced cancer. Cancer Treat Rep 1987;71:11711177.
  • 7
    Wiernik PH, Schwartz EL, Straumann JJ, et al. Phase I clinical and pharmakokinetic study of Taxol. Cancer Res 1987;47:24862493.
  • 8
    Rowinsky EK, Chaundhry V., Cornblath DR, et al. The neuro-toxicity of Taxol. J Natl Cancer Inst Monogr 1993;15:107.
  • 9
    Rowinsly EK, Burke PJ, Karp JE, et al. Phase I and pharmaco-dynamic study of Taxol in refractory acute leukemias. Cancer Res 1989;49:46404647.
  • 10
    Keia MG, O'Connell JP, Gralla RJ, et al. Phase I study of Taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep 1986;70:605607.
  • 11
    Rowinsky EK, McGuire WP, Guarnieri T., et al. Cardiac disturbances during the administration of Taxol. J Clin Oncol 1991;9:1704.
  • 12
    Arbuck SG, Strauss H., Rowinsky EK, et al. A reassessment of the cardiac toxicity associated with Taxol. J Natl Cancer Inst Monog 1993;15:117.
  • 13
    Einzig AL, Wiernik PH, Sasloff J., et al. Phase II study and long-term follow-up of patients treated with Taxol for advanced ovarian cancer. J Clin Oncol 1992;10:17481753.
  • 14
    Gatzemeier U., Heckmayr M., Neuhauss R., et al. Phase II study with paclitaxel for the treatment of advanced inoperable non–small cell lung caner. Lung Cancer 1995;12:S101S106.
  • 15
    Swain SM, Honig SF, Tefft MC, et al. A phase II trial of pac-litaxel (Taxol) as first line treatment in advanced breast cancer. Invest New Drugs 1995;13(3):217222.
  • 16
    Alberola V., Rosell R., Gonzalez-Larriba JL, et al. Single agent Taxol, 3-hour infusion, in untreated advanced non-small-cell lung cancer. Ann Oncol 1995;6:S49S52.
  • 17
    Einzig AI, Hochster H., Wiernik PH, et al. A phase II study in patients with malignant melanoma. Invest New Drugs 1991;9(1):5964.
  • 18
    Ogilvie GK, Moore AS, Vail DM, et al. Toxicoses associated with the administration of paclitaxel to dogs with measurable malignancies: A dose escalation study. Veterinary Cancer Society 16th Annual Meeting, Pacific Grove, CA; 1996: 2829.
  • 19
    National Cancer Institute Common toxicity criteria, version 3.0. Available at: Accessed June 10, 2003
  • 20
    Hershey AE, Kurzman ID, Forrest LJ, et al. Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: Proof of principle using dogs with spontaneously occuring tumors as a model. Clin Cancer Res 1999;5(9):26532659.
  • 21
    Rowinsky EK, Eisenhauer EA, Chaudhry V., et al. Clinical tox-icity encountered with Taxol. Semin Oncol 1993;20(Suppl 3):1.
  • 22
    Ajani JA, Dodd LG, Daugherty K., et al. Taxol-induced soft-tissue injury secondary to extravasation: Characterization by histopa-thology and clinical course. J Natl Cancer Inst 1994;86:51.
  • 23
    Gian VG, Johnson TL, Marsh RW, et al. A phase II trial of paclitaxel in treatment of recurrent or metastatic soft tissue sarcomas or bone sarcomas. J Exp Ther Oncol 1996;1(3):186190.
  • 24
    Patel SR, Papadopoulos NE, Plager C., et al. Phase II study of paclitaxel in patients with previously treated osteosarcoma and its variant. Cancer 1996;78(4):741744.